We suggest that these 4 TCRs might be predictive biomarkers for the treatment effects of patients with stage II/III NSCLC with an EGFR mutation who received adjuvant treatment with gefitinib or chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.